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INTRODUCTION
Long QT-syndrome (LQTS) is a genetic cardiac channelopa-
thy characterised by a prolonged QT interval on a surface
electrocardiogram (ECG), syncope, T-wave abnormalities, ventri-
cular tachycardia of the torsades de pointes (TdPVT) type (Fig. 1)
and an increased risk of sudden death [1]. LQTS has variable
clinical presentation and is genetically characterised by in-
complete penetrance, as seen in many other cardiac genetic
conditions [2].
Historically, LQTS is divided into a congenital and an
acquired form. Four clinical types of congenital LQTS (cLQTS)
have been defined. The commonest is the Romano-Ward
syndrome (RWS), with autosomal dominant inheritance and
a prevalence of approximately 1 in 2,500 [1]. The other three
variants known are much rarer. These are: Jervell-Lange Nie-
lsen syndrome (JLNS), wherein LQTS is associated with con-
genital deafness and the pattern of inheritance is autosomal
recessive; Andersen syndrome (AS), where LQTS is variably
present together with other arrhythmias, periodic paralysis and
malformations; and the very rare Timothy syndrome (TS), cha-
racterised by a more malignant form of LQTS, cardiac and
other somatic malformations, and autism [3, 4].
The acquired form of LQTS (aLQTS) presents itself with
a normal QT-interval on the ECG under normal conditions, but
a prolonged interval under the influence of drug-intake or struc-
tural heart disease [5]. The aLQTS occurs much more frequen-
tly than cLQTS, and (interestingly) may have a genetic element
that makes the individual more susceptible to certain drugs.
The clinical diagnosis of LQTS is made using the dia-
gnostic criteria given in Table 1 [6]. As seen, it comprises
ECG findings, a clinical history of syncope and a family hi-
story of LQTS or sudden cardiac death. Importantly, the QT
interval increases with decreasing heart rate, making it
necessary to use a rate-corrected QT interval termed QTc
(QTc = QT/÷RR) when assessing whether the interval is pro-
longed or normal [7]. Presently, the diagnostic criteria do
not involve the results from genetic testing, but such testing
is necessary to identify asymptomatic carriers and relatives
of affected individuals who may otherwise present clinically
with sudden death as the first symptom [8]. As beta-adre-
nergic blockade or the application of an ICD unit may dra-
matically reduce the risk of cardiac events, there exists
a real treatment option in LQTS [9].
The aim of this review is to give an update on the expan-
ding number of genes known to be associated with LQTS
and their pathophysiological mechanisms.
GENES INVOLVED IN LQTS
Changes in the QT interval duration are caused by an altered
time course of the cardiac action potential (AP). An AP consi-
sts of depolarisation, plateau and repolarisation phases which
reflect the electrical activity across the cardiomyocyte plasma
membrane during one contraction, i.e. from systole until the
next diastole. This activity is generated by a number of ion
channels and can be influenced by various effector systems
such as the autonomous nervous system. The most signifi-
cant ion channels involved in forming the AP are given in
Figure 2, along with their individual time-voltage relationship.
The LQTS can be described as a cardiac channelopathy re-
sulting from elevated inward depolarising currents or dimini-
shed outward repolarising currents of the AP that lead to
a prolongation of the QT interval [10].
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To date, 12 different genes have been associated with
LQTS. These include sodium, potassium and calcium chan-
nels as well as interactors of the various channels and chan-
nel subunits. Mutations in these genes may result in the loss
[11–22] or gain of function [23, 24] and are summarised in
Table 2.
METHODS OF MUTATION SCREENING
A variety of techniques are employed to detect the genetic
variants in LQTS. For the application of these methods in
a clinical setting, it is important that they are inexpensive,
rapid and that their sensitivity as well as their specificity exce-
eds 97%. Direct sequencing by capillary array electropho-
resis (CAE) is still considered the ‘gold standard’ although it
is too expensive to be a first line mutation detection me-
thod. Single strand conformation polymorphism (SSCP) ana-
lysis and denaturing high performance liquid chromatogra-
phy (DHPLC) provide cheaper options [25–27]. These tech-
niques can be optimised and modified for greater sensitivity
and specificity and to cut down the labour required, altho-
ugh in certain cases it still takes a lot of time for analyses.
Resources required for screening can be reduced by sensi-
bly selecting genes for analysis [28]. However, compound
heterozygotes, digenic inheritance, and modifying genes
highlight the importance of a comprehensive screening stra-
tegy including all genes [29, 30].
Figure 1. A. An ECG of an LQT2 patient with prolonged QT-interval (underlined), and bifid T-wave (*) and notched T-wave (**);
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GENOTYPE-PHENOTYPE CORRELATION
Correlations between the genotype and phenotype in the
LQTS are complicated by the fact that in many LQTS genes,
very few mutations have been identified. Intra-allelic hetero-
geneity also plays a role, as mutations in the same gene may
confer different risks of cardiac events due to the location of
the mutation, and the phenotype of the LQTS-gene associa-
ted with the disease may vary between affected family mem-
bers. Complex phenotypes such as BrS, CCD as well as struc-
tural heart disease, (such as DCM), involving LQTS have been
reported [31, 32].
For LQT1, LQT2 and LQT3 correlations of the genotype
with prognosis and risk of cardiac events have been perfor-
med [33]. These three types of LQTS also have characteristic
T-wave differences on the ECG [34]. Repeating these investi-
gations with other LQT types is difficult, as there is limited
data available. However, LQT7 patients exhibit a distinct ECG
with characteristic U-waves [35]. JLNS and TS (LQT8) carry
a particularly high risk of sudden cardiac death from early
childhood onwards [23, 36].
CLINICAL SIGNIFICANCE OF MUTATION
IDENTIFICATION IN LQTS-ASSOCIATED GENES
The simple findings of mutations in LQTS-associated genes are
not sufficient to claim that they are the cause of the disease. Apart
from single mutations, there are numerous polymorphisms which
contribute to the number of sequence variants observed. Many
of these variants have been associated with repolarisation as well
as cardiac conduction defects and have been proposed as dise-
ase-modifying factors. The pathological significance of a muta-
tion is only very occasionally supported by genetic linkage. Evi-
dence for pathogenicity can be obtained if functional analysis is
performed to determine the effect of a particular LQTS-associa-
ted mutation. This can be achieved by doing electrophysiologi-
cal studies of mutated ion channel subunits expressed in vitro in
order to compare it to known pathophysiological mechanisms.
Figure 2. Ionic channels involved in formation of action
potential. The sodium current (INa) is represented by blue,
the long lasting calcium current (ICa-L) by green, four different
potassium currents (IKs, IKr, IK1, Ito) by yellow, and the sodium
calcium exchange current (INa/Ca) by red




≥ 480 ms1/2 3
460–470 ms1/2 2
450 (males) 1
Torsades de pointes*** 2
T-wave alternans 1
Notched T-wave in three leads 1







Family members with definite LQTS****** 1
Unexplained sudden cardiac death before the age
of 30 among immediate family members 0.5
*In the absence of medications or disorders known to affect these
electrocardiographic features; **QTc calculated by Bazett’s formula,
where QTc = QT/÷RR; ***Mutually exclusive;****Resting heart rate below
the second percentile for age; *****The same family member cannot be
counted in A and B. Low probability of LQTS is defined by an LQTS score
£ 1 point; an intermediate probability of LQTS is defined by an LQTS
score of 2 to 3 points; ≥ 4 points indicates a high probability of LQTS
(Modified from Schwartz et al. [6])
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The first reported LQTS-associated mutations were found in
the potassium voltage-gated channel, KQT-like subfamily,
member 1 (KCNQ1) gene (MIM# 607542). The KCNQ1 gene
is located on the short arm of chromosome 11 and contains
16 exons which range in size from 47 to 1,122 bp [37]. This
gene belongs to a large family of genes that provide instruc-
tions for making potassium channels. It encodes a 75 kDa pro-
tein consisting of 676 amino acids [37]. This is an alpha-subu-
nit of the slow producing voltage-gated potassium channel
(Kv7.1) (Fig. 3A) which conducts the slow delayed rectifier K+
current (IKs) (Fig. 2). It contributes to the repolarisation of the
cell, terminating the plateau phase of cardiac action potential
(AP) and thereby also the heart’s contractions [38]. Kv7.1 co-
assembles with a beta subunit called minK which plays an im-
portant role in modulating the current of this channel [38].
To date, more than 250 mutations in KCNQ1 have been
implicated with LQTS type 1 (LQT1 – MIM# 192500) [9]. It
has been shown that mutations of Kv7.1 alter the function of
IKs due to defective trafficking and dominant-negative loss-of-
-function effects [39, 40]. Moreover, several mutations have been
reported that affect the binding of interacting proteins [41].
KCNH2
Another frequently mutated gene in LQTS is KCNH2, a po-
tassium voltage-gated channel, subfamily H, member 2 gene
(MIM# 15427). This gene was mapped to chromosome 7
and contains 15 exons [13, 42]. It encodes a protein consi-
sting of 1,159 amino acids and is highly expressed in the he-
Table 2. The genes associated with long QT syndrome
Type Syndrome Gene Protein Function Mechanism Characteristics Prevalence
and triggers in LQTS patients
LQT1 RWS, JLNS KCNQ1 Kv7.1 a subunit IKs Loss-of-function Arrhythmia triggered by exercise, 40–55%
swimming and emotion
LQT2 RWS KCNH2 Kv11.1 a subunit IKr Loss-of-function Arrhythmia triggered by sound 35–45%
or emotion
LQT3 RWS SCN5A Nav1.5 a subunit INa Gain-of-function Arrhythmia triggered by sleep, 2–8%
rest and emotion
LQT4 RWS ANK2 Ankyrin B Adaptor Loss-of-function Arrhythmia triggered by exercise < 1%
(INa-K, INa-Ca, INa)
LQT5 RWS, JLNS KCNE1 minK b subunit IKs Loss-of-function Arrhythmia triggered by exercise < 1%
and emotion
LQT6 RWS KCNE2 MiRP1 b subunit IKr Loss-of-function Arrhythmia triggered by rest < 1%
and exercise
LQT7 AS KCNJ2 Kir2.1 a subunit IK1 Loss-of-function Syndromic, arrhythmia triggered by rest < 1%
and exercise, frequent ectopy
LQT8 TS CACNA1C Cav1.2 a subunit ICa Gain-of-function Syndromic, early onset and death < 1%
from arrhythmia
LQT9 RWS CAV3 M-Caveolin Adaptor (INa) Loss-of-function Rest and sleep triggers arrhythmia < 1%
LQT10 RWS SCN4B Navb4 b subunit INa Loss-of-function Exercise triggers arrhythmia < 0.1%
LQT11 RWS AKAP9 Yotiao Adaptor (IKs) Loss-of-function Exercise triggers arrhythmia < 0.1%
LQT12 RWS SNTA1 a1-Syntrophin Scaffolding Loss-of-function Rest triggers arrhythmia < 0.1%
protein (INa)
RWS — Romano-Ward syndrome; JLNS — Jervell and Lange-Nielsen syndrome; AS — Andersen syndrome; TS — Timothy syndrome. Modified from
Hedley et al. [9]
Figure 3. Schematic drawings of voltage-dependent potassium
channels Kv7.1 (A) and Kv11.1 (B) with intracellular C- and
N-terminus and six trans-membrane domains
A B
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art [42]. This protein is an alpha-subunit of the voltage-gated
potassium ion channel Kv11.1 (previously known as HERG)
(Fig. 3B) which conducts the repolarising cardiac rapidly acti-
vating delayed rectifier K+ current (IKr) (Fig. 2) [43]. Kv11.1 co-
assembles with the beta subunit MiRP1 which modulates the
potassium current of this channel, drastically affecting the
length of the plateau phase of the cardiac action potential
[11]. When this channel’s ability to conduct electrical current
across the cell membrane is inhibited or compromised by
the application of drugs or by occurring mutations, it can re-
sult in LQTS [43].
To date, more than 300 mutations have been reported
in KCNH2 associated with LQTS type 2 (LQT2 – MIM#
152427) [9]. Mutations in KCNH2 result in many different
dysfunctions of the Kv11.1 channel, including trafficking de-
ficiencies and the formation of non-functional channels or
channels with altered gating properties [44].
SCN5A
Sodium channel dysfunctions in congenital LQTS are largely
due to mutations in the SCN5A gene. This sodium voltage-
gated channel, type V, alpha subunit gene (MIM# 600163)
was mapped to chromosome 3 by fluorescence in situ hybri-
disation [45]. It consists of 28 exons that span approximately
80 kb, and 65% of LQT3-causing mutations are found in exons
20–28 [46]. SCN5A encodes a protein of 2,016 amino acids
which is structurally very similar to that of other depolarising
sodium channels. This protein forms the a-subunit of the car-
diac sodium channel Nav1.5 (Fig. 4). Nav1.5 conducts the
sodium inward current (INa) (Fig. 2) which is responsible for
the initial depolarisation of cardiomyocytes [9].
Mutations in SCN5A that are associated with LQTS (LQT3
– MIM# 603830) characteristically produce an increased late
INa and consequently prolonged repolarisation [47]. The
SCN5A LQTS-associated mutations mainly act through a gain-
of-function mechanism which means that although the mu-
tant channel functions normally, certain properties are alte-
red, the most frequent being fast inactivation [47].
ANK2
The first protein implicated in a congenital long QT syndro-
me that is not an ion channel or channel subunit is called
Ankyrin B. It is coded for by ANK2 (MIM# 600919). The ANK2
gene is located on the long arm of chromosome 4 and consi-
sts of 46 exons, of which exon 38 is brain-specific [48]. Anky-
rin B is a member of a larger family of versatile membrane
adapters (ankyrin-R, ankyrin-B, ankyrin-G and tissue-specific
splice forms) required for organising, transporting and ancho-
ring membrane protein complexes to the actin/spectrin cyto-
skeleton. Among other molecules, ankyrins bind a number
of ion motive proteins essential for cardiac electrophysiology
in general including the Na+/Ca2+ exchanger; inositol 1,4,5-
-triphosphate receptor and Na+/K+ ATPase [49].
The loss-of-function mutations identified in ANK2 (LQT4
– MIM# 600919) are associated with dominantly inherited
type LQT4 in humans [50]. All these mutations result in ab-
normal co-ordination of multiple functionally-related ion
channels and transporters such as the Na+/Ca+ exchanger
which is involved in Ca2+ release during cardiac excitability
and can lead to a complex of phenotypes including LQTS,
sinus bradycardia, cathecolaminergic polymorphic ventricu-
lar tachycardia, idiopathic ventricular fibrillation and sudden
death [15, 51].
KCNE1 and KCNE2
Two other genes involved in the congenital long QT syndro-
me encode ion channel beta-subunits of the KCNE family.
Their protein products form single trans-membrane domain
ancillary subunits that co-assemble with voltage-gated potas-
sium (Kv) channel a-subunits modifying their function. The
first one is called KCNE1, which is the potassium voltage-ga-
ted channel, IsK related subfamily member 1 gene (MIM#
176261). KCNE1 is located on the long arm of chromoso-
me 21. It consists of three exons, with the third exon encoding
the 129 amino acid protein [37, 52]. This protein, called the
minimal potassium channel (minK), co-assembles with a-sub-
units of Kv7.1 (Fig. 3A) forming channels that conduct the
slowly activating delayed rectifier K+ (IKs) current (Fig. 2) [38].
Mutations in the KCNE1 gene that are associated with
LQTS (LQT5 – MIM# 176261) are characterised by reducing
the potassium flux. There is evidence to suggest that KCNE1
plays a role in channel recycling which alters the IKs current
[53]. The importance of minK in regulating the function of
the Kv7.1 channel is emphasised by the fact that a number of
inherited mutations in KCNE1 result not only in long QT syn-
drome but also in deafness due to the reduced IKs in the inner
ear [17, 54]. The combination of deafness with LQTS is cal-
led JLNS and has a very poor prognosis [36].
Figure 4. Schematic drawing of the sodium voltage-gated
channel Nav1.5 containing four homologous domains, DI-DIV,
each of which has six putative membrane-spanning regions.
DI-IV — domains 1-4; PDZ — PDZ structural domain; PH1 —
pleckstrin homology domain1; PH2 — pleckstrin homology
domain2; SU — syntrophin unique domain
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The second member of the KCNE family is KCNE2.
KCNE2 is the potassium voltage-gated channel, IsK-related
subfamily, member 2 gene (MIM# 603796). This gene is lo-
cated on the long arm of chromosome 21 and consists of two
exons. The second exon encodes the 123 amino acid prote-
in [11]. This protein, known as the minimum potassium ion
channel related peptide 1 (MiRP1), functions as a small inte-
gral membrane b-subunit associated with the a-subunits of
the Kv11.1 ion channels (Fig. 3B). Together, these subunits
conduct the rapidly activating delayed rectifier (IKr) current
(Fig. 2) [11, 55].
Mutations in KCNE2 associated with LQTS (LQT6 –
MIM# 603796) are characterised by a reduction of the po-
tassium flux generated by the IKr current resulting in delayed
repolarisation [11, 17]. Furthermore, KCNE2 mutations may
also cause the acquired form of the LQTS [56].
KCNJ2
A further potassium channel involved in LQTS and influen-
cing the cardiac action potential is encoded by the KCNJ2
gene. KCNJ2 is the potassium inward rectifying channel, sub-
family J, member 2 gene (MIM# 600681). This gene is loca-
ted on the long arm of chromosome 17 and contains two
exons which span approximately 10 kb [57]. The KCNJ2 gene
encodes a 427 amino acid protein (Kir2.1) (Fig. 5) which forms
a voltage-dependent inwardly rectifying potassium ion chan-
nel responsible for conducting a significant part of the inwar-
dly rectifying IK1 current (Fig. 2). IK1 is important for stabilising
the resting membrane potential, defining the excitation thre-
shold and modulating repolarisation [58]. The activity of the
Kir 2.1 channel is highly dependent on the integrity of chan-
nel interactions with phosphatidylinositol 4,5-bisphosphate
(PIP2) [59].
By genetic linkage studies in a large family, Plaster et
al. [16] identified mutations in KCNJ2 that were also asso-
ciated with Andersen syndrome (LQT7 – MIM# 170390).
Andersen syndrome (AS) is inherited in an autosomal do-
minant fashion and is characterised by periodic paralysis,
cardiac arrhythmias and dysmorphic features [60]. Further-
more, there is a high variability and incomplete penetran-
ce in AS. LQTS is the primary cardiac manifestation, pre-
sent in 71% of patients with AS, and dominant-negative
loss-of-function mutations in KCNJ2 result in malfunctio-
ning Kir2.1 channels [3]. This is also the reason that LQT7
remains the name of this type of LQT. However, it should
be noted that LQT7 is associated with bidirectional ventri-
cular tachycardia (VT), premature ventricular contraction
(PVC) and extrasystoles [35]. Sudden death is rare when
compared to other LQT-types.
CACNA1C
Calcium channel dysfunctions in the congenital LQTS are
related to mutations in CACNA1C, the calcium voltage-de-
pendent channel, L type, alpha-1C subunit gene (MIM#
114205). CACNA1C is located on the short arm of chromo-
some 12 and contains 50 exons [61]. This gene encodes an
a-1 subunit of a voltage-dependent calcium channel, known
as CaV1.2 (Fig. 6) which mediates the depolarising influx of
calcium ions (IL,Ca current) (Fig. 2) into the cell and contribu-
tes to the plateau phase of the cardiac action potential. Mul-
tiple isoforms of the a-1 subunit protein exist and they often
have different electrophysiological and pharmacological pro-
perties [62].
Mutations in CACNA1C have been described in patients
with Timothy syndrome (LQT8 – MIM# 601005) [4, 23]. Ti-
mothy syndrome (TS) is a rare autosomal dominant disorder
characterised by physical malformations, as well as neurolo-
Figure 5. Schematic drawing of the voltage-dependent
inwardly rectifying potassium ion channel Kir 2.1 composed
of two trans-membrane domains (M1 and M2) separated by
a pore-associated extracellular domain. The location of known
LQTS-associated mutations is indicated by red spots
Figure 6. Schematic drawing of the calcium voltage-dependent
channel composed of four homologous domains (DI-DIV) each
consisting of six trans-membrane segments. The location of the
two LQTS-associated mutations is indicated by red dots
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gical and developmental defects, including heart QT-prolon-
gation, heart arrhythmias, structural heart defects, immune
deficiency, intermittent hypoglycaemia, syndactyly, autism
and baldness at birth. Timothy syndrome often results in ear-
ly death [4]. Mutations in CACNA1C associated with LQTS
were identified in differentially spliced exons 8 and 8A. The
complete lack of voltage-dependent inactivation in these
mutants results in prolonged Ca2+ inward current during the
plateau phase of the AP. This leads to Ca2+ overload and de-
layed repolarisation [23].
CAV3
As previously mentioned, LQTS is also associated with muta-
tions in genes encoding proteins that interact with the ion
channel subunits. The second interacting protein, other than
ankyrin B, which has been implicated with the LQTS is enco-
ded by the caveolin-3 (CAV3) gene (MIM# 601253). CAV3 is
located on chromosome 3 and consists of two exons [63]. It
encodes a 196 amino acid protein called M-caveolin (CAV3)
(Fig. 4) a principal protein in caveolae which are membrane
invaginations that participate in localising membrane prote-
ins at the membrane surface [64]. It is only expressed in the
heart and skeletal muscle. Among other functions, such as
intracellular sorting of lipids or proteins, CAV3 modulates the
INa current by interactions with membrane components inc-
luding the a-subunit of Nav1.5 [65].
Vatta et al. [21] analysed the CAV3 gene in 905 unrela-
ted patients with LQT (LQT9 – MIM# 611818) and identi-
fied loss-of-function mutations in six of them. It has been
shown that the interaction of the mutant caveolin-3 with the
Nav1.5 ion channel results in a two to five-fold increase in
the late INa which is consistent with pathological mechanisms
previously described in LQT3 [66].
SCN4B
Another sodium channel involved in LQTS is encoded by the
SCN4B gene. This is the sodium voltage-gated channel, type IV,
beta subunit gene (MIM# 608256). SCN4B is located on chro-
mosome 11 and contains five exons [67]. Its protein product
consists of 228 amino acids and forms the b4-subunit of the
cardiac sodium channel (Fig. 4) responsible for the conduc-
tion of the INa current (Fig. 2). Yu et al. [67] determined that
the biophysical function of the b-subunit is to modify the func-
tion of Nav1.5 by slightly inhibiting the INa.
Medeiros-Domingo et al. [14] analysed the SCN4B gene
in a Mexican-mestizo family with LQTS (LQT10 – MIM#
611819) and they identified a mutation which, when expres-
sed in HEK293 cells stably expressing the Nav1.5 ion chan-
nel, causes a dramatic eight-fold increase in the late sodium
current. This effect is very similar to that observed with LQT3-
-associated mutations in SCN5A.
AKAP9 and SNTA1
Recently, two additional genes with LQTS-associated muta-
tions involved in controlling ion channels function have been
identified. The first encodes a protein which is a member of
the A-kinase anchor proteins (AKAPs), while the second is
a member of the syntrophin protein family.
AKAP proteins are a group of structurally diverse prote-
ins which target cAMP-dependent protein kinase A (PKA) to
facilitate PKA mediated phosphorylation [68]. LQTS-associa-
ted mutations were reported in one of the AKAP members
known as the A-kinase anchor protein 9 (AKAP9) gene (MIM#
604001). AKAP9 is located on chromosome 7 and comprises
51 exons [69]. This gene encodes two proteins, the human
homologue of the rat protein, AKAP120 and a 1,626 amino
acid protein also known as yotiao (Fig. 3A) [69]. In the heart,
yotiao is involved in the phosphorylation of a number of pro-
teins including the ryanodine receptor, the L-type Ca2+ chan-
nel and the potassium channel responsible for the slow repo-
larising current, IKs [70–72].
Chen et al. [12] analysed the AKAP9 gene in 50 LQTS
families where no mutations were detected in the other known
LQTS-associated genes. They discovered a single mutation
located in close proximity to the C-terminal Kv7.1 binding
site (LQT11 – MIM# 611820). Further investigation showed
that this inherited mutation reduces, but does not eliminate,
the interaction between yotiao and Kv7.1. It reduces the
cAMP-dependent phosphorylation of Kv7.1 and alters the
functional response of IKs channels to cAMP, resulting in de-
layed repolarisation of the ventricular action potential [12].
 Syntrophins are cytoplasmic sub-membranous proteins
that are components of the dystrophin-associated protein
complex containing multiple protein interaction motifs. LQTS-
-associated mutations were identified in the syntrophin,
a1 (SNTA1) gene (MIM# 601017) which forms part of this
group. The SNTA1 gene is located on chromosome 20 and
consists of eight exons [73]. It encodes a 505 amino acid pro-
tein called a1-syntrophin (Fig. 4) which acts as a scaffolding
protein for neural nitric oxide synthase (nNOS), plasma mem-
brane Ca2+-ATPAse (PMCA) and the a-subunit of Nav1.5 at
the C-terminus [74].
The STNA1 gene was analysed in 50 unrelated LQTS
patients for whom no mutations have been reported in the
other LQTS-associated genes. One missense mutation was
identified in a patient with a seriously prolonged QTc interval
on the ECG (LQT12- MIM# 601017) [20]. Functional stu-
dies showed that the mutation causes increased nitrosylation
of Nav1.5 and increases the late sodium current. This is con-
sistent with previous reports about LQT3-associated muta-
tions in SCN5A. Additionally, the mutation disrupts the link
between Ca2+ transporting, plasma membrane 4 (PMCA4b)
and the Nav1.5/a1-syntrophin complex [20].
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CONCLUSIONS
To date, mutations in 12 genes have been associated with
LQTS. The spectrum of genes involved is rapidly increasing,
and recent findings point to the significance of proteins inte-
racting or modulating cardiac ion channels. Identification of
disease-causing mutations is important as it may help identify
asymptomatic gene carriers that could benefit from prophy-
lactic beta-adrenergic blockade or application of an ICD unit.
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